MA43271A - Formulations améliorées de déférasirox et leurs procédés de fabrication - Google Patents

Formulations améliorées de déférasirox et leurs procédés de fabrication

Info

Publication number
MA43271A
MA43271A MA043271A MA43271A MA43271A MA 43271 A MA43271 A MA 43271A MA 043271 A MA043271 A MA 043271A MA 43271 A MA43271 A MA 43271A MA 43271 A MA43271 A MA 43271A
Authority
MA
Morocco
Prior art keywords
improved
manufacturing processes
deferasirox
formulations
deferasirox formulations
Prior art date
Application number
MA043271A
Other languages
English (en)
Inventor
Justin M Keen
Sandra U Kucera
Dave A Miller
Original Assignee
Dispersol Technologies Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dispersol Technologies Llc filed Critical Dispersol Technologies Llc
Publication of MA43271A publication Critical patent/MA43271A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA043271A 2015-06-17 2016-06-17 Formulations améliorées de déférasirox et leurs procédés de fabrication MA43271A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562180998P 2015-06-17 2015-06-17

Publications (1)

Publication Number Publication Date
MA43271A true MA43271A (fr) 2018-09-26

Family

ID=57546755

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043271A MA43271A (fr) 2015-06-17 2016-06-17 Formulations améliorées de déférasirox et leurs procédés de fabrication

Country Status (10)

Country Link
US (4) US10265301B2 (fr)
EP (1) EP3310354B1 (fr)
JP (1) JP2018517734A (fr)
CN (1) CN107847490A (fr)
AU (3) AU2016280280B2 (fr)
CA (1) CA2989145C (fr)
HK (1) HK1254608A1 (fr)
IL (1) IL256322B (fr)
MA (1) MA43271A (fr)
WO (1) WO2016205658A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2565279T3 (en) 2007-12-05 2015-02-16 Complete Genomics Inc Efficient base determination in sequencing reactions
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
CN102459592B (zh) 2009-06-15 2017-04-05 考利达基因组股份有限公司 用于长片段阅读测序的方法和组合物
US10837879B2 (en) 2011-11-02 2020-11-17 Complete Genomics, Inc. Treatment for stabilizing nucleic acid arrays
CZ2017255A3 (cs) * 2017-05-04 2018-11-14 Zentiva, K.S. Filmem potažené tablety Deferasiroxu
US11331288B2 (en) 2017-09-14 2022-05-17 The Board Of Trustees Of The Leland Stanford Junior University Conditioning irradiated tissue for increasing vascularity
CN111511365A (zh) * 2017-11-10 2020-08-07 分散技术有限责任公司 改进的药物制剂
EP3852711A4 (fr) * 2018-09-20 2022-06-08 Tautona Group IP Holding Company, L.L.C. Composés de chélation du fer pour traiter des affections cutanées esthétiques
EP4096791A1 (fr) 2020-01-31 2022-12-07 Nanocopoeia LLC Microparticules de nilotinib amorphe et leurs utilisations
IL297776A (en) 2020-04-30 2022-12-01 Nanocopoeia Llc Orally disintegrating tablets containing an amorphous solid dispersion of nalotinib
CN112870361A (zh) * 2021-01-28 2021-06-01 重庆医科大学 铁死亡抑制剂在制备预防或治疗铁过载导致的骨质疏松或骨丢失的药物中的应用
CN114994205B (zh) * 2022-05-30 2023-03-28 上海奥科达医药科技股份有限公司 地拉罗司颗粒剂中相关杂质的检测方法
WO2025151876A1 (fr) * 2024-01-11 2025-07-17 Minneamrita Therapeutics Llc Formulations de triptolide

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0009056D0 (en) * 2000-04-12 2000-05-31 Nestle Sa Composition comprising free amino acids
RU2008119410A (ru) * 2005-10-19 2009-11-27 Новартис АГ (CH) Диспергируемые таблетки, включающие деферасирокс
WO2009026461A2 (fr) 2007-08-21 2009-02-26 Board Of Regents, The University Of Texas System Mélange thermocinétique pour des applications pharmaceutiques
EP2062572A1 (fr) * 2007-11-19 2009-05-27 Teva Pharmaceutical Industries Ltd. Compositions pharmaceutiques
EP2291360A2 (fr) * 2008-04-21 2011-03-09 Actavis Group PTC ehf. Formes à l'état solide de sels de déférasirox et leurs procédés de fabrication
JP2013512893A (ja) * 2009-12-07 2013-04-18 マピ ファーマ リミテッド デフェラシロクスの調製方法、及びデフェラシロクスの多形体
KR20130041144A (ko) * 2010-07-08 2013-04-24 라티오팜 게엠베하 데페라시록스의 경구투여용 제제
WO2012025935A2 (fr) * 2010-08-25 2012-03-01 Ramamohan Rao Davuluri Procédé de préparation de 2-(2-hydroxyphényl)-benz[1,3]oxazin-4-one et son utilisation pour la préparation d'acide 4-[3, 5-bis (2-hydroxyphényl)-1h-1, 2, 4-triazol-1-yl]-benzoïque
PE20170468A1 (es) * 2010-10-01 2017-04-26 Cipla Ltd Composicion farmaceutica que comprende deferasirox
US20140039031A1 (en) * 2011-02-23 2014-02-06 Dispersol Technologies. LLC Pharmaceutical formulations of acetyl-11-keto-b-boswellic acid, diindolylmethane, and curcumin for pharmaceutical applications
SG11201506491RA (en) * 2013-03-08 2015-09-29 Novartis Ag Oral formulations of deferasirox
HK1215191A1 (zh) * 2013-05-10 2016-08-19 Cipla Limited 低剂量医药组合物

Also Published As

Publication number Publication date
AU2016280280B2 (en) 2021-09-02
IL256322B (en) 2022-03-01
JP2018517734A (ja) 2018-07-05
US11878005B2 (en) 2024-01-23
US20170296514A1 (en) 2017-10-19
CN107847490A (zh) 2018-03-27
AU2021277731B2 (en) 2024-04-11
US10265301B2 (en) 2019-04-23
HK1254608A1 (zh) 2019-07-26
AU2024202528A1 (en) 2024-05-09
IL256322A (en) 2018-02-28
US10258608B2 (en) 2019-04-16
CA2989145A1 (fr) 2016-12-22
AU2021277731A1 (en) 2021-12-23
EP3310354A1 (fr) 2018-04-25
EP3310354C0 (fr) 2026-02-25
CA2989145C (fr) 2024-10-29
EP3310354A4 (fr) 2018-12-12
EP3310354B1 (fr) 2026-02-25
US20170027911A1 (en) 2017-02-02
AU2016280280A1 (en) 2018-01-04
WO2016205658A1 (fr) 2016-12-22
US20240091201A1 (en) 2024-03-21
AU2024202528B2 (en) 2026-01-08
US20190167643A1 (en) 2019-06-06

Similar Documents

Publication Publication Date Title
EP3310354C0 (fr) Formulations améliorées de déférasirox et leurs procédés de fabrication
EP3662518A4 (fr) Dispositifs nanoporeux à micro-del et leurs procédés de fabrication
EP3731652A4 (fr) Produits de protéines de pois chiches et leurs procédés de fabrication
EP3867936A4 (fr) Éponges nano-graphitiques et leurs procédés de fabrication
MA44869A (fr) Cellules génétiquement modifiées et leurs procédés de fabrication
MA48475A (fr) Procédés de fabrication de niraparib
EP3292582A4 (fr) Cellules d'électrochloration à volume réduit et leurs procédés de fabrication
DE102016200026B8 (de) Wafer-Herstellungsverfahren
EP3314245A4 (fr) Capteurs biomoléculaires et procédés associés
EP3352577A4 (fr) Compositions à base de cannabinoïdes et leurs procédés de production
EP3378101A4 (fr) Pérovskites multicouches, dispositifs, et leurs procédés de fabrication
EP3503879A4 (fr) Compositions et procédés associés
EP3357101A4 (fr) Dispositifs photovoltaïques en pérovskite à hétérojonction et leurs procédés de fabrication
MA46474A (fr) Formulations nanoparticulaires et leurs procédés de production et d'utilisation
MA53939A (fr) Compositions hémostatiques et leurs procédés de fabrication
EP3370543A4 (fr) Produits d'insecte et leurs procédés de fabrication
MA51879A (fr) Plaques de plâtre et leurs méthodes de fabrication
EP3679607A4 (fr) Matériaux de pérovskite organiques-inorganiques et leurs procédés de fabrication
FR3033247B1 (fr) Cages intervertebrales et leurs applications
EP3393292A4 (fr) Articles de fixation et leurs procédés de fabrication
EP3538628A4 (fr) Compositions oligomères synthétiques et leurs procédés de fabrication
EP3448300A4 (fr) Implants bioniques et leurs procédés de fabrication
EP3433587A4 (fr) Balance et procédés associés
EP3413710A4 (fr) Surfaces structurées antibactériennes et leurs procédés de fabrication
EP3724933A4 (fr) Composés supraconducteurs et procédés de fabrication associés